Clinical Effectiveness of Ovine Forestomach Matrix Graft in Complex Lower Limb Reconstruction and Limb Salvage

¹M. Mark Melin (MD, FACS, RPVI); ²Richard Kaufman (DPM); ³James E. Geiger, Jr. (DPM); ⁴Igor Zilberman ¹M Health- Fairview, Edina, MN, USA; ²Piedmont Atlanta Hospital, Atlanta, GA, USA; ³Northwestern Medical Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, Davie, FL, USA ⁵Sharp Chula Vista Medical Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Florida Lower Extremity Center, San Diego, CA, USA; ⁴Couth Center, San Diego, CA, USA; ⁴Couth Center, San Diego, CA, USA

INTRODUCTION

Chronic low extremity defects may lead to major amputations and have severe consequences on patient quality of life, and ultimately, mortality[1]. There are several pathways to surgical closure of these defects with robust coverage of any exposed vital structures (i.e. bone, tendon, arteries) or volumetric fill often being the initial goal. Ovine forestomach matrix scaffold (OFM) technology has been developed as a robust planar sheet or particulate form which can be utilized in volumetric, contaminated wounds to rapidly build tissue and provide cover to exposed structures with viable granulation, ultimately shortening the time to definitive closure. The OFM graft format is indicated for dermal regeneration and implant procedures.

METHODS


A total of 50 case records were evaluated (n=50) across seven (7) healthcare centers across the United States. Case records were reviewed to identify; patient comorbidities, defect etiology (e.g. NSTI, DFU, burn, etc.), defect size, presence of exposed structures, CDC contamination score, Wagner score, OFM graft usage, time to 100% granulation tissue, STSG usage, overall time to heal and any post-operative complications. Patient demographics, baseline wound characteristics and healing outcomes were analyzed with descriptive statistics.

CONCLUSION

This IRB-approved retrospective case series demonstrates OFM as a clinically effective treatment modality in the surgical management of complex lower extremity soft tissue defects with exposed structures and multi-morbid patients. A single application of the graft was effective in regenerating well vascularized neodermis, often in the presence of exposed structures within 26.0±22.2 days, in a complex patient cohort who might otherwise have lost extremities to amputation[2]. These data support the use of OFM as a safe, costeffective, and clinically effective treatment option to granulate over exposed vital structures and shorten time to definitive closure.

REFERENCES AND DISCLOSURES

[♦]Myriad Matrix[™] and Myriad Morcells[™] (Aroa Biosurgery Limited, New Zealand). [1] Meshkin DH, Zolper EG, Chang K, Bryant M, Bekeny JC, Evans KK, Attinger CE, Fan KL. Long-term Mortality After Nontraumatic Major Lower Extremity Amputation: A Systematic Review and Meta-analysis. J Foot Ankle Surg. 2021 May-Jun;60(3):567-576. . [2]. Flood, M. S., B. Weeks, K. O. Anaeme, H. Aguirre, K. B. Hobizal, S. E. Jiongco, R. J. Klein, A. Lemoi, R. Rafols and A. S. Landsman (2020). "Treatment of Deep Full-thickness Wounds Containing Exposed Muscle, Tendon, and/or Bone Using a Bioactive Human Skin Allograft: A Large Cohort Case Series." Wounds 32(6): 164-173.



Week 0: Initial Presentation

Example Case #1: Staged procedure with STSG. 28-year-old male diabetic - Wagner 4, necrotizing infection. Week 0: Partial ray Week 1: 100% Granulation Week 3: 90% STSG take Week 5: Healed resection, exposed tendon tissue – place STSG and bone





Week 0: Pre-operative presentation





Example Case #3: Dermal regeneration. 62-year-old female diabetic, PAD - Pyoderma Gangrenosum.

Week 0: Initial Presentation

Week 0: Intra-operative application of OFM, covering exposed tendon





Example Case #2: Dermal regeneration. 39-year-old female diabetic - deep partial-thickness burn.

Week 2: Healed after one OFM application

Week 12: Long-term follow-up, remains fully epithelialized



Week 7: 100% granulation – coverage of exposed tendon, residual OFM noted

Week 21: Application Week 26: Healed, of STSG

no recurrence as of 5 months